Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines
Introduction The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflam...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/1/e088267.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524906522574848 |
|---|---|
| author | Rachelle Buchbinder Peter Tugwell Pablo Alonso-Coello Mickael Hiligsmann Nick Bansback Laurie Proulx Dawn P Richards Wojtek Wiercioch Glen Hazlewood Samuel Whittle Jordi Pardo Pardo Marie Falahee Holger Schünemann Robby Nieuwlaat Pakeezah Saadat Simon Kuper |
| author_facet | Rachelle Buchbinder Peter Tugwell Pablo Alonso-Coello Mickael Hiligsmann Nick Bansback Laurie Proulx Dawn P Richards Wojtek Wiercioch Glen Hazlewood Samuel Whittle Jordi Pardo Pardo Marie Falahee Holger Schünemann Robby Nieuwlaat Pakeezah Saadat Simon Kuper |
| author_sort | Rachelle Buchbinder |
| collection | DOAJ |
| description | Introduction The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.Methods and analysis We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarise included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.Ethics and dissemination Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals. |
| format | Article |
| id | doaj-art-8a91bf153ae040f58fd9d9764cbe9555 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-8a91bf153ae040f58fd9d9764cbe95552025-01-18T00:00:08ZengBMJ Publishing GroupBMJ Open2044-60552025-01-0115110.1136/bmjopen-2024-088267Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelinesRachelle Buchbinder0Peter Tugwell1Pablo Alonso-Coello2Mickael Hiligsmann3Nick Bansback4Laurie Proulx5Dawn P Richards6Wojtek Wiercioch7Glen Hazlewood8Samuel Whittle9Jordi Pardo Pardo10Marie Falahee11Holger Schünemann12Robby Nieuwlaat13Pakeezah Saadat14Simon Kuper159 Musculoskeletal Health and Wiser Health Care Units, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia7 Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada16 Centro GRADE Barcelona, Instituto de Investigacion Biomedica, Barcelona, Spain6 Department of Health Services Research, CAPHRI Care and Public Health research Institute, Maastricht University, Maastricht, Netherlands2 School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada12 Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada12 Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada14 Department of Medicine, McMaster University, Hamilton, Ontario, Canada22 McCaig Institute for Bone and Joint Health, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada10 School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia20 Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada4 Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK13 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada14 Department of Medicine, McMaster University, Hamilton, Ontario, Canada1 Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada19 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Limburg, NetherlandsIntroduction The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.Methods and analysis We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarise included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.Ethics and dissemination Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals.https://bmjopen.bmj.com/content/15/1/e088267.full |
| spellingShingle | Rachelle Buchbinder Peter Tugwell Pablo Alonso-Coello Mickael Hiligsmann Nick Bansback Laurie Proulx Dawn P Richards Wojtek Wiercioch Glen Hazlewood Samuel Whittle Jordi Pardo Pardo Marie Falahee Holger Schünemann Robby Nieuwlaat Pakeezah Saadat Simon Kuper Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines BMJ Open |
| title | Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| title_full | Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| title_fullStr | Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| title_full_unstemmed | Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| title_short | Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| title_sort | patient preferences for drug therapy in inflammatory arthritis protocol for a living systematic review and evidence map to inform clinical practice guidelines |
| url | https://bmjopen.bmj.com/content/15/1/e088267.full |
| work_keys_str_mv | AT rachellebuchbinder patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT petertugwell patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT pabloalonsocoello patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT mickaelhiligsmann patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT nickbansback patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT laurieproulx patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT dawnprichards patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT wojtekwiercioch patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT glenhazlewood patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT samuelwhittle patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT jordipardopardo patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT mariefalahee patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT holgerschunemann patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT robbynieuwlaat patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT pakeezahsaadat patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines AT simonkuper patientpreferencesfordrugtherapyininflammatoryarthritisprotocolforalivingsystematicreviewandevidencemaptoinformclinicalpracticeguidelines |